NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has received conditional approval from the New York State Department of Health (NYSDOH) for its allele-specific PCR-based assays designed to test for BRAF, EGFR, KRAS, and NRAS mutations in lung, colon, and melanoma cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.